Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q3 2019 · 10-Q
Revenue$237.00K$237.00K−99.4% vs Q3 2018 Net Income-$39.30M-$39.30MN/M vs Q3 2018 EPS Diluted-$0.06-$0.06N/M vs Q3 2018 Operating Income-$40,121,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$29,831,000N/M Margins · derivedOperating margin-16928.7%−16945.9 pt vs Q3 2018
Net margin-16583.1%−16596.0 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 6, 2019 · 37 d after period end